Do Elevated BNP Levels Predict Hemodynamically Significant PDAs
Completed
Conditions studied: Patent Ductus Arteriosus
In brief
The purpose of this study is to determine if B type natriuretic peptide (BNP) levels can be used to predict a hemodynamically significant patent ductus arteriosus (PDA). This peptide is produced by the ventricles in the heart when they are under stress, such as when a ductus remains open. If we can use a simple and inexpensive blood test to determine whether a PDA needs to be treated, we can potentially treat infants sooner than if they needed to wait for the availability of a cardiologist to perform an echocardiogram. This might decrease some of the deleterious effects of PDAs on the preterm infant such as bronchopulmonary dysplasia, necrotizing enterocolitis, renal hypoperfusion, and pulmonary hemorrhage. In a situation where follow up echocardiogram after a course of medical therapy shows persistent PDA, this test may help to decide whether this baby needs further treatment, either medical or surgical.
Key facts
- Study ID
- NCT01497054
- Run by
- Albany Medical College
- People needed
- 109
- Starts
- 2011-12-01
- Expected to finish
- 2013-04-01
- Last updated by the study team
- 2013-07-04
Who can join
Age: any, up to 0. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- gestational age between 24 0/7 weeks gestation and 31 6/7 weeks gestation. - Infants must be enrolled by 24 hours of life.
You may not qualify if…
- congenital heart disease,
- necrotizing enterocolitis,
- culture positive sepsis or culture negative but treated for presumed sepsis.
Where it is running
- Albany Medical Center Neonatal Intesive Care Unit — Albany, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.